Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
Carcinoma · Non-Small-Cell Lung · Lung Cancer (NSCLC) · Lung Neoplasms · Carcinoma, Non-Small-Cell Lung (NSCLC) · Lung Disease · Non-Small Cell Lung Cancer · Non-small Cell Lung Cancer, Non-squamous · Non-small Cell Lung Cancer, Squamous
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 120 (planned)
- Started
- Jun 30, 2026
- Main results expected
- Jul 29, 2028
- Fully finished
- Jul 30, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants With Adverse Events (AEs)
Measured over: Through 90 days after the last dose of study intervention (Part A only: or 90 days after surgery, whichever is later)
Part A: Surgical Feasibility Rate
Measured over: Up to approximately 6 months after first dose
Part A: Pathological Complete Response (pCR) rate per International Association for the Study of Lung Cancer (IASLC) guidelines as assessed by central pathology review
Measured over: Up to approximately 6 months after first dose
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07489066 · record last updated 2026-10-08 · checked 2026-11-09 15:36 UTC